Keitaro Matsuo Selected Research

Imatinib Mesylate (Gleevec)

9/2018	Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
4/2017	Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
4/2014	Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.
1/2012	Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.
6/2009	Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
11/2008	Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
2/2008	Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
1/2006	High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
12/2004	Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keitaro Matsuo Research Topics

Disease

135	Neoplasms (Cancer) 01/2024 - 01/2002
57	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2002
44	Stomach Neoplasms (Stomach Cancer) 10/2023 - 04/2002
34	Lung Neoplasms (Lung Cancer) 05/2021 - 04/2002
33	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 10/2004
28	Colorectal Neoplasms (Colorectal Cancer) 10/2023 - 01/2002
16	Leukemia 01/2021 - 04/2002
15	Carcinogenesis 01/2023 - 01/2001
13	Infections 11/2023 - 01/2001
13	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 04/2002
12	Hematologic Neoplasms (Hematological Malignancy) 12/2023 - 01/2008
12	Head and Neck Neoplasms (Head and Neck Cancer) 10/2023 - 07/2007
11	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 03/2007
11	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 01/2001
11	Pancreatic Neoplasms (Pancreatic Cancer) 05/2021 - 10/2008
10	Atrophy 01/2019 - 01/2003
10	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2018 - 02/2003
9	Neoplasm Metastasis (Metastasis) 01/2023 - 04/2010
9	Inflammation (Inflammations) 01/2022 - 04/2003
9	Lymphoma (Lymphomas) 08/2019 - 01/2001
9	Adenocarcinoma 10/2014 - 09/2007
8	Squamous Cell Carcinoma of Head and Neck 10/2023 - 01/2006
8	Adenocarcinoma of Lung 01/2021 - 05/2002
7	Flushing 01/2023 - 05/2006
7	Colonic Neoplasms (Colon Cancer) 01/2018 - 04/2002
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 04/2002
6	Endometrial Neoplasms (Endometrial Cancer) 01/2023 - 03/2007
6	Ovarian Epithelial Carcinoma 01/2023 - 07/2014
6	Philadelphia Chromosome 09/2018 - 02/2008
6	Rectal Neoplasms (Rectal Cancer) 01/2018 - 01/2002
6	Rheumatoid Arthritis 01/2018 - 09/2005
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2010 - 05/2008
4	Hypertension (High Blood Pressure) 01/2022 - 03/2007
4	Obesity 01/2022 - 05/2010
4	Urinary Bladder Neoplasms (Bladder Cancer) 07/2020 - 12/2015
4	Disease Progression 01/2020 - 01/2007
4	Laryngeal Neoplasms (Laryngeal Cancer) 01/2019 - 07/2015
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 08/2003

Drug/Important Bio-Agent (IBA)

39	ORALIT (ORS)IBA 01/2023 - 03/2002
23	Biomarkers (Surrogate Marker)IBA 01/2023 - 05/2002
21	Folic Acid (Vitamin M)FDA LinkGeneric 01/2024 - 01/2002
21	EnzymesIBA 10/2023 - 01/2001
21	ErbB Receptors (EGF Receptor)IBA 03/2023 - 04/2006
20	Estrogen ReceptorsIBA 01/2021 - 10/2002
18	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 02/2004
16	Hormones (Hormone)IBA 03/2024 - 01/2002
16	Proteins (Proteins, Gene)FDA Link 10/2023 - 12/2011
16	Aldehyde DehydrogenaseIBA 12/2020 - 01/2001
11	Coffee FDA Link 01/2022 - 03/2007
10	Gefitinib (Iressa)FDA Link 03/2023 - 02/2005
10	AcetaldehydeIBA 07/2020 - 07/2005
9	Imatinib Mesylate (Gleevec)FDA Link 09/2018 - 12/2004
9	AntigensIBA 01/2018 - 08/2005
7	CarbonIBA 10/2023 - 12/2005
7	Tyrosine Kinase InhibitorsIBA 03/2023 - 05/2006
7	TeaIBA 01/2022 - 04/2012
7	Estrogens (Estrogen)FDA Link 05/2021 - 03/2007
7	Fatty Acids (Saturated Fatty Acids)IBA 06/2014 - 01/2005
7	Cisplatin (Platino)FDA LinkGeneric 06/2013 - 10/2004
7	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 05/2010 - 04/2004
6	LipidsIBA 12/2022 - 01/2005
6	Indicators and Reagents (Reagents)IBA 09/2020 - 11/2009
6	Transcription Factors (Transcription Factor)IBA 01/2020 - 04/2013
6	PlatinumIBA 02/2018 - 05/2009
6	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 08/2002
6	Alcohol Dehydrogenase (Alcohol Dehydrogenase (NAD+))IBA 01/2016 - 05/2006
6	Thymidylate SynthaseIBA 05/2010 - 02/2003
5	AldehydesIBA 01/2023 - 11/2016
5	HLA Antigens (Human Leukocyte Antigens)IBA 09/2022 - 04/2005
5	Ethanol (Ethyl Alcohol)IBA 01/2022 - 01/2009
5	Pepsinogen A (Pepsinogen)IBA 08/2019 - 01/2003
5	lysyllysine (Lys-Lys)IBA 01/2019 - 03/2002
5	5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase (Methyltetrahydrofolate Homocysteine Methyltransferase)IBA 10/2008 - 01/2001
4	Rituximab (Mabthera)FDA Link 10/2023 - 07/2008
4	HLA-C Antigens (HLA-C)IBA 09/2022 - 03/2007
4	SmokeIBA 01/2022 - 02/2003
4	LigandsIBA 05/2019 - 03/2007
4	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 10/2008
4	human ERBB2 proteinIBA 01/2019 - 10/2008
4	HLA-DRB1 Chains (HLA DRB1)IBA 01/2018 - 12/2011
4	glutamyl-glutamic acid (Glu-Glu)IBA 06/2016 - 03/2002
4	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2016 - 02/2005
4	Carotenoids (Carotene)IBA 01/2016 - 05/2006
4	Docetaxel (Taxotere)FDA Link 06/2011 - 07/2002
4	Oxidoreductases (Dehydrogenase)IBA 07/2009 - 01/2001
4	methionine synthase reductaseIBA 10/2008 - 01/2002
4	InterleukinsIBA 04/2003 - 01/2001

Therapy/Procedure

43	Drug Therapy (Chemotherapy) 10/2023 - 08/2002
33	Therapeutics 01/2024 - 07/2002
12	Hematopoietic Stem Cell Transplantation 01/2024 - 12/2004
11	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2021 - 07/2006
10	Adjuvant Chemotherapy 01/2023 - 10/2004
6	Cell Transplantation 02/2024 - 08/2003
6	Stem Cell Transplantation 01/2024 - 08/2005
6	Radiotherapy 10/2023 - 01/2007
6	Transplantation 08/2016 - 04/2002
5	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2021 - 04/2002
5	Combination Drug Therapy (Combination Chemotherapy) 06/2013 - 11/2009
4	Lymph Node Excision (Lymph Node Dissection) 10/2023 - 07/2008
4	Chemoradiotherapy 12/2017 - 04/2010